Vistagen Therapeutics, Inc. (VTGN)
0.3079
+0.01
(+3.32%)
USD |
NASDAQ |
Sep 30, 16:00
0.2952
-0.01
(-4.12%)
After-Hours: 20:00
Vistagen Therapeutics EPS Diluted (Quarterly) : -0.3032 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3032 |
| March 31, 2026 | -0.4108 |
| December 31, 2025 | -0.4475 |
| September 30, 2025 | -0.5432 |
| June 30, 2025 | -0.4727 |
| December 31, 2024 | -0.4588 |
| September 30, 2024 | -0.4231 |
| June 30, 2024 | -0.3507 |
| March 31, 2024 | -0.3523 |
| December 31, 2023 | -0.2161 |
| September 30, 2023 | -0.656 |
| June 30, 2023 | -0.9358 |
| March 31, 2023 | -1.707 |
| December 31, 2022 | -1.416 |
| September 30, 2022 | -2.536 |
| June 30, 2022 | -2.872 |
| March 31, 2022 | -2.424 |
| December 31, 2021 | -1.593 |
| September 30, 2021 | -2.045 |
| June 30, 2021 | -1.280 |
| March 31, 2021 | -6.075 |
| December 31, 2020 | -2.091 |
| September 30, 2020 | -1.630 |
| June 30, 2020 | -2.024 |
| March 31, 2020 | -2.289 |
| Date | Value |
|---|---|
| December 31, 2019 | -4.368 |
| September 30, 2019 | -3.976 |
| June 30, 2019 | -4.584 |
| March 31, 2019 | -4.637 |
| December 31, 2018 | -7.337 |
| September 30, 2018 | -9.00 |
| June 30, 2018 | -6.00 |
| March 31, 2018 | -5.70 |
| December 31, 2017 | -7.50 |
| September 30, 2017 | -15.90 |
| June 30, 2017 | -8.40 |
| March 31, 2017 | -9.60 |
| December 31, 2016 | -10.20 |
| September 30, 2016 | -12.60 |
| June 30, 2016 | -15.30 |
| March 31, 2016 | -133.20 |
| December 31, 2015 | -58.50 |
| September 30, 2015 | -157.80 |
| June 30, 2015 | -576.90 |
| March 31, 2015 | -127.20 |
| December 31, 2014 | -25.20 |
| September 30, 2014 | -57.00 |
| June 30, 2014 | -114.00 |
| March 31, 2014 | -48.00 |
| December 31, 2013 | -12.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Onconetix, Inc. | -1.278 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -13.03M |
| Revenue (Quarterly) | 1.476M |
| Total Expenses (Quarterly) | 14.51M |
| Enterprise Value | -17.72M |
| Gross Profit Margin (Quarterly) | 86.65% |
| Profit Margin (Quarterly) | -882.8% |
| Earnings Yield | -553.7% |
| Normalized Earnings Yield | -553.59 |